| Risk | High |
|---|---|
| Min SIP Amount | ₹1000 |
| Expense Ratio | 0.85% |
| NAV | ₹14.65 (10 Jul 2020) |
|---|---|
| Fund Started | 25 Jun 2018 |
| Fund Size | ₹640 Cr |
| Name | Sector | Instrument | % Assets |
|---|---|---|---|
| Sun Pharmaceutical Inds. Ltd. | Healthcare | Equity | 12.1% |
| Dr. Reddy's Laboratories Ltd. | Healthcare | Equity | 11.5% |
| Divi's Laboratories Ltd. | Healthcare | Equity | 7.8% |
| Aurobindo Pharma Ltd. | Healthcare | Equity | 6.4% |
| Biocon Ltd. | Healthcare | Equity | 5.6% |
| Lupin Ltd. | Healthcare | Equity | 5.3% |
| Ipca Laboratories Ltd. | Healthcare | Equity | 4.7% |
| Cipla Ltd. | Healthcare | Equity | 4.3% |
| Ajanta Pharma Ltd. | Healthcare | Equity | 4.0% |
| Apollo Hospitals Enterprise Ltd. | Healthcare | Equity | 3.1% |
Mirae Asset Healthcare Fund Direct Growth is a Equity Mutual Fund Scheme launched by Mirae Asset Mutual Fund. This scheme was made available to investors on 25 Jun 2018. Neelesh Surana is the Current Fund Manager of Mirae Asset Healthcare Fund Direct Growth fund.The fund currently has an Asset Under Management(AUM) of ₹640 Cr and the Latest NAV as of 10 Jul 2020 is ₹14.65.
The Mirae Asset Healthcare Fund Direct Growth is rated High risk. Minimum SIP Investment is set to 1000. Minimum Lumpsum Investment is 5000. Exit load of 1% if redeemed within 1 year.
The scheme seeks to generate long term capital appreciation through investing in equity and equity related securities of companies benefitting directly or indirectly in Healthcare and allied sectors in India.
Returns are taxed at 15%, if you redeem before one year. After 1 year, you are required to pay LTCG tax of 10% on returns of Rs 1 lakh+ in a financial year.